Kelun-Biotech's Sac-TMT Combination Therapy Shows Promise in EGFR-Mutant NSCLC
Event summary
- Translational research published in *Cancer Cell* demonstrates that EGFR-TKIs upregulate TROP2 in drug-tolerant persister cells, supporting the combination of sac-TMT with osimertinib.
- Phase III study (NCT06670196) of sac-TMT plus osimertinib vs. osimertinib monotherapy for advanced EGFR-mutant NSCLC has completed enrollment and is in follow-up phase.
- Phase II study (NCT07329322) exploring sac-TMT in neoadjuvant setting for resectable EGFR-mutant NSCLC is ongoing.
The big picture
Kelun-Biotech is positioning sac-TMT as a key combination partner for EGFR-TKIs, addressing the critical challenge of drug resistance in NSCLC. The company's strategic focus on ADC technology and global collaborations with MSD underscores its ambition to become a leader in oncology innovation. The publication in *Cancer Cell* strengthens the scientific rationale for this approach, while ongoing clinical trials will determine its commercial potential.
What we're watching
- Clinical Trial Outcomes
- Whether the Phase III study will demonstrate superior efficacy of sac-TMT plus osimertinib over osimertinib monotherapy in first-line EGFR-mutant NSCLC.
- Regulatory Approvals
- The pace at which sac-TMT's new indication application with pembrolizumab advances through China's NMPA priority review process.
- Global Expansion
- How MSD's 17 ongoing global Phase III studies of sac-TMT will impact its commercialization outside Greater China.
Related topics